The Kendall Square Association (KSA) is a membership-based organization that consists of companies and institutions committed to promoting the health, vitality and vibrancy of Kendall Square in Cambridge, Massachusetts. Website
Robins Kaplan LLP is among the nation’s premier trial law firms, with more than 220 attorneys in six major cities. Our attorneys litigate, mediate, and arbitrate client disputes, always at-the-ready for an ultimate courtroom battle. When huge forces are at play, major money is at stake, or rights are being trampled, we help clients cut through complexity, get to the heart of the problem, and win what matters most. We are clearly focused on business results for our clients. We achieve landmark triumphs and drive thousands of other cases to resolution before they ever hit the courtroom or the front page. From Big Tobacco to Kraft v. Starbucks, Interchange to Bhopal and the World Trade Center—we have changed law, business, and society for the better by redefining what’s possible. Website
Since 1941, the people of Southern Research Institute have contributed to mankind’s quality of life through advancements leading to life-saving drugs, safer space exploration, cleaner air and energy production, and enhanced national defense. Southern Research is a not-for-profit, 501(c)(3) organization conducting basic and applied research in Alabama, Maryland, and North Carolina in the areas of drug discovery, preclinical drug development, advanced engineering, and environmental protection. Southern Research is a self-sustaining contract research organization and an incorporated affiliate of The University of Alabama at Birmingham (UAB). We are brought together because of a shared belief in the power and potential of collaborative research. Southern Research and UAB have long-standing relationships in areas such as materials engineering, high-performance computing, breast cancer research, glial biology, cystic fibrosis research, and gene therapy. Website
1) Obama Proposes U.S. Spending to Research Personalized Cures – Bloomberg, January 20, 2015
President Barack Obama will urge Congress to spend U.S. taxpayers’ money for research in “precision medicine,” a burgeoning field of care in which treatments are tailored to an individual patient. Link
2) Novartis scores the first victory in a blockbuster psoriasis race – FierceBiotech, January 21, 2015
Novartis ($NVS) has picked up FDA and European approvals to sell its secukinumab as a treatment for psoriasis, the first steps in the company’s plot to build a global anti-inflammatory contender and outpace its rivals. Link
3) Supreme Court’s Teva ruling carries implications for future drug patent cases – Modern Healthcare, January 20, 2015
The U.S. Supreme Court on Tuesday vacated a lower court’s ruling that had ended patent protection for Teva Pharmaceuticals’ multiple sclerosis drug Copaxone. The decision could have broader implications for how courts decide future pharmaceutical patent disputes. Link
4) Johnson & Johnson Announces Formation of Ebola Vaccine Development Consortia, Gains Funding from Innovative Medicines Initiative – Fierce Biotech , January 16, 2015
Johnson & Johnson (JNJ) is pleased to announce the formation of consortia with leading global research institutions and non-government organizations to work in conjunction with Janssen Pharmaceutical Companies to accelerate the development of its Ebola vaccine regimen. Link
5) Taking Stock: Coughlin Says Vertex Adding Women to Board – Bloomberg, January 16, 2015
Taking Stock with Carol Massar and Michael McKee. GUEST: Robert Coughlin President/CEO Massachusetts Biotechnology Council Discussing the need for more women in STEM fields with Gloria Larson President Bentley University Betsy Myers Founding Director Center for Women & Business. Link
Earlier this month, MassBioEd supported Diman Regional Vocational Technical High School’s “in-school field trip” where 33 ninth-grade students spent the day doing an advanced biotechnology lab. Each student used modern techniques to examine his or her own DNA to determine if he or she had the gene needed to taste a certain bitter chemical, PTC.
Diman teachers Barbara Souza, Liss O’Connell and Maureen Cooney, led the experiment with support from MassBioEd BioTeach mentor Whitney Hagins and MIT postdoctoral fellow Eric Williams. The students’ first step was to test their ability to taste PTC and make predictions about what they expected to see on their gel based upon their results. The experiment began with the isolation and extraction of DNA from each student. Then a polymerase chain reaction amplified the gene necessary for tasting PTC and the gene was analyzed by restriction digests and gel electrophoresis. The excitement was palpable as students waited to see their own DNA on the electrophoresis gels. Through this experiment, both teachers and students gained a deeper understanding of applications for biotechnology.
CRELUX is a provider of high-quality research services in early-stage drug development. Its core expertise lies in the production of prime proteins and their use in biophysical compound screenings and protein crystallography. The privately-owned company has established itself as a reliable premium partner for the global pharma and biotech industry. As a research partner, CRELUX has a portfolio of premium technologies and top-level expertise in protein biochemistry. These include innovations in protein expression for the production of ultra-pure protein for use in research and diagnostics (PRIME PROTEIN services), a wide selection of target proteins for X-ray crystallography that are relevant for human therapy (XPRESS portfolio), customised programmes for the solution of new protein structures (XPERT service) and innovative technology for fragment and compound screening (INTRACT). Integrated structure based drug discovery solutions including hit-to-lead and lead compound optimization steps are marketed by CRELUX under the label i2c (idea to candidate). Website.
Located in downtown Seattle’s biotech corridor, Seattle Children’s Research Institute is pushing the boundaries of medical research to find cures for pediatric diseases and improve outcomes for children all over the world. Internationally recognized investigators and staff at the research institute are advancing new discoveries in cancer, genetics, immunology, pathology, infectious disease, injury prevention and bioethics, among others. As part of Seattle Children’s Hospital, the research institute brings together leading minds in pediatric research to provide patients with the best care possible. Seattle Children’s serves as the primary teaching, clinical and research site for the Department of Pediatrics at the University of Washington School of Medicine, which consistently ranks as one of the best pediatric departments in the country. Website.
Zafgen Inc. is an early-stage biotechnology company focused on novel treatments for obesity. Utilizing a capital-efficient, virtual approach through a world-leading advisory team, Zafgen focuses on the highest-quality preclinical programs to achieve superior efficacy, safety and intellectual property positions. Website.
1) J.P. Morgan Healthcare Conference deal roundup – The Boston Globe, January 14, 2015
As investors digested headline-grabbing deals unspooled at the outset of the J.P. Morgan Healthcare Conference, including big acquisitions disclosed by Massachusetts biotechs Shire PLC, Biogen Idec Inc., and Foundation Medicine Inc., other mostly smaller deal announcements have continued to trickle out at the investors gathering this week. Link
2) US FDA approves AbbVie’s treatment for Parkinson’s – The Irish Times, January 12, 2015
The US Food and Drug Administration approved AbbVie’s treatment for Parkinson’s disease, three months ahead of the scheduled review date. Link
3) In biotech, patient advocates’ voices heard – The Boston Globe, January 12, 2015
The voices of patients and their advocates are growing louder at life sciences industry events like the J.P. Morgan Healthcare Conference, which opened here Monday. While curing and treating patients has always been the focus of the booming business of drug and medical device makers, the patients themselves were conspicuously absent when drug executives in suits and ties gathered in the past. Link
4) J.P. Morgan Breaking News: Novartis AG (NVS), Google Inc. (GOOG) to Team Up on “Smart” Contact Lens, Says CEO – BioSpace, January 12, 2015
Swiss drugmaking behemoth Novartis (NVS) will be teaming with Google (GOOG) on a possible “smart” contact lens to be available in a few years, the company said during a presentation Monday, during which is also mapped out its plans for drug trials in 2015 and touted its new emphasis on business ethics. Link
5) Top biotech investor NEA outlines plans for another $2.5B-plus venture fund – FierceBiotech, January 14, 2015
In a sign of the times, leading life sciences venture maven David Mott and his colleagues at New Enterprise Associates have begun raising a whopping $2.5 billion venture fund–less than three years after rolling out its latest fund with $2.6 billion. Link